Stockscreener 앱 받기
26.73
2.33%
0.60
전일 마감가:
$26.13
열려 있는:
$26.94
하루 거래량:
136.88K
Relative Volume:
0.20
시가총액:
$2.99B
수익:
$418.33M
순이익/손실:
$-252.07M
주가수익비율:
-11.14
EPS:
-2.4
순현금흐름:
$-238.84M
1주 성능:
+1.52%
1개월 성능:
-20.77%
6개월 성능:
-14.24%
1년 성능:
-12.21%
1일 변동 폭
$26.63
$27.25
1주일 범위
$25.13
$27.25
52주 변동 폭
$23.82
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
명칭
Zai Lab Limited Adr
전화
862161632588
주소
4560 JINKE ROAD, SHANGHAI
ZLAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
26.74 | 2.91B | 418.33M | -252.07M | -238.84M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.97 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.67 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.67 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.64 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.94 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-03-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-14 | 개시 | Morgan Stanley | Overweight |
| 2023-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-01-21 | 개시 | Macquarie | Outperform |
| 2021-10-12 | 개시 | Bernstein | Mkt Perform |
| 2020-04-28 | 개시 | Goldman | Buy |
| 2020-04-15 | 개시 | Guggenheim | Buy |
| 2019-07-12 | 개시 | BofA/Merrill | Buy |
| 2019-07-05 | 개시 | Macquarie | Outperform |
| 2019-01-29 | 개시 | Credit Suisse | Outperform |
| 2018-11-21 | 개시 | Jefferies | Buy |
| 2018-06-21 | 재개 | Leerink Partners | Outperform |
| 2018-02-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 개시 | JP Morgan | Neutral |
| 2017-10-16 | 개시 | Leerink Partners | Outperform |
모두보기
Zai Lab Limited Adr 주식(ZLAB)의 최신 뉴스
Zai Lab (NasdaqGM:ZLAB): Evaluating Valuation Following Promising Trial Results and Phase 3 Progress - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zai Lab (ZLAB) to Release Quarterly Earnings on Thursday - MarketBeat
Zai Lab Announces Participation in Investor Conferences in November and December 2025 - The Globe and Mail
Zai Lab Announces Participation in Investor Conferences in September 2025 - FinancialContent
Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.6%Time to Sell? - MarketBeat
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study - Business Wire
Q3 Earnings Estimate for Zai Lab Issued By Leerink Partnrs - MarketBeat
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? - MSN
Zai Lab Secures RMB300 Million Debt Facility - The Globe and Mail
[8-K] Zai Lab Ltd Reports Material Event | ZLAB SEC FilingForm 8-K - Stock Titan
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 - The Globe and Mail
Zai Lab (NASDAQ:ZLAB) Trading Down 6.2%Here's What Happened - MarketBeat
Late‑breaking Phase 1 data for Zoci: Zai Lab to present DLL3‑targeted ADC results at AACR Oct 24, 2025 - Stock Titan
Operating cash flow per share of Zai Lab Ltd. Sponsored ADR – BER:1ZL - TradingView
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - Business Wire
Trip.com Group LimitedAmerican Depositary Shares (NQ: - FinancialContent
Is Zai Lab's Valuation Justified as Revenue Growth Lags the Biotech Industry (ZLAB)? - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ETFs Investing in Zai Lab Ltd. Sponsored ADR Stocks - TradingView
Zai Lab Limited Announces Equity Incentive Grants to Employees - MSN
Zai Lab (NASDAQ:ZLAB) Shares Gap UpStill a Buy? - MarketBeat
Zai Lab Limited Depositary Receipt Stock Analysis and ForecastStochastic Oscillator Alerts & High Profit Trading Signals - Early Times
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Zai Lab (ZLAB) - The Globe and Mail
How robust is Anheuser Busch Inbev SA Sponsored ADR stock financial position2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
Zai Lab Limited Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsZLAB - ACCESS Newswire
Acadian Asset Management LLC Buys New Shares in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Levi & Korsinsky Reminds Shareholders of an Investigation into Zai Lab Limited (ZLAB) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Lost Money on Zai Lab Limited (ZLAB)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Consensus Price Target from Analysts - MarketBeat
Shareholder Rights Advocates at Levi & Korsinsky Investigate Zai Lab Limited (ZLAB) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Insider Buying: Zai Lab (NASDAQ:ZLAB) Insider Purchases 10,000 Shares of Stock - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Average PT from Brokerages - Defense World
Woodline Partners LP Sells 558,781 Shares of Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Gap DownTime to Sell? - MarketBeat
Zai Lab Limited ADR (NASDAQ: ZLAB) Is Up 14.37% – Is It Capable Of A Rally? - stocksregister.com
FY2026 EPS Estimates for Zai Lab Reduced by Leerink Partnrs - MarketBeat
Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB) - 富途牛牛
Raymond James Financial Inc. Boosts Holdings in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Cubist Systematic Strategies LLC Increases Stake in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga
Zai Lab under pressure over clinical results and rival drugs - thebambooworks.com
Why Zai Lab (ZLAB) Is Down 5.5% After Diminished Final Results for Bemarituzumab in Gastric Cancer - Sahm
Zai Lab FY2026 EPS Forecast Lowered by Leerink Partnrs - Defense World
Canada Pension Plan Investment Board Buys New Shares in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
MPM Bioimpact LLC Acquires 33,659 Shares of Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Frazier Life Sciences Management L.P. Makes New Investment in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab Limited Adr (ZLAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.96%
자본화:
|
볼륨(24시간):